Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its participation in two scheduled healthcare conferences in March 2025, where the company’s leadership team will provide insights into its …
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its fourth quarter and full-year 2024 financial results, along with key pipeline advancements and corporate updates signaling a pivotal year ahead.
Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug that acts as a covalent inhibitor of two key immune signaling kinases, ITK …
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the creation of its new Scientific Advisory Board (SAB), marking a strategic step in advancing its focus on immuno-inflammatory diseases. The …
Aclaris Therapeutics Forms Scientific Advisory Board with Renowned Pulmonology Experts Read More